A turning point in the fight against ovarian cancer?

Affiliations

¹ Department of Woman and Child Health, Woman Health Area, Gynecologic Oncology Unit Fondazione "Policlinico Universitario A Gemelli", Catholic University, Rome 00168, Italy. Electronic address: giovanni.scambia@policlinicogemelli.it.
² Department of Woman and Child Health, Woman Health Area, Gynecologic Oncology Unit Fondazione "Policlinico Universitario A Gemelli", Catholic University, Rome 00168, Italy.

Comment

Giovanni Scambia et al. Lancet Oncol. 2018 Feb.

. 2018 Feb;19(2):154-156.

doi: 10.1016/S1470-2045(18)30005-6. Epub 2018 Jan 18.

¹ Department of Woman and Child Health, Woman Health Area, Gynecologic Oncology Unit Fondazione "Policlinico Universitario A Gemelli", Catholic University, Rome 00168, Italy. Electronic address: giovanni.scambia@policlinicogemelli.it.
² Department of Woman and Child Health, Woman Health Area, Gynecologic Oncology Unit Fondazione "Policlinico Universitario A Gemelli", Catholic University, Rome 00168, Italy.

No abstract available

Comment on

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
Lee JM, Nair J, Zimmer A, Lipkowitz S, Annunziata CM, Merino MJ, Swisher EM, Harrell MI, Trepel JB, Lee MJ, Bagheri MH, Botesteanu DA, Steinberg SM, Minasian L, Ekwede I, Kohn EC. Lee JM, et al. Lancet Oncol. 2018 Feb;19(2):207-215. doi: 10.1016/S1470-2045(18)30009-3. Epub 2018 Jan 18. Lancet Oncol. 2018. PMID: 29361470 Free PMC article.